At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 29 enrolled
Drug / intervention
sildenafildrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Vasodilator Therapy and Exercise Tolerance in IPF Patients
In Brief
A Phase 2 clinical trial evaluating sildenafil for Alveolitis, Fibrosing and 2 related conditions. Completed, enrolled 29 participants across 1 site.
Detailed Summary
Medicines that decrease blood pressure in the lungs may help idiopathic pulmonary fibrosis (IPF) patients function better. This study will test whether sildenafil improves the ability to exercise in patients with pulmonary fibrosis of unknown cause.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2006
First PostedAug 2006
Primary CompletionOct 2008
Study CompletionJun 2009
TodayJul 2026
First PostedAug 2, 2006
Enrollment StartJul 1, 2006
Primary CompletionOct 1, 2008
Study CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 19.9 years ago
Interventions
sildenafildrug
Assessing the possible therapeutic benefit of sildenafil on exercise tolerance in IPF patients.